Stayble Therapeutics AB (publ) (STO: STABL)
Sweden
· Delayed Price · Currency is SEK 0.492
-0.033 (-6.29%)
Dec 6, 2024, 5:29 PM CET
Stayble Therapeutics AB Company Description
Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration.
The company develops STA363, an injection into the disc that targets chronic low back and leg pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Stayble Therapeutics AB (publ)
| Country | Sweden |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Andreas Gerward |
Contact Details
Address: Lennart Torstenssonsgatan 6 Gothenburg, 412 56 Sweden | |
| Website | staybletherapeutics.se |
Stock Details
| Ticker Symbol | STABL |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0013513652 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andreas Gerward M.Sc. | Co-Founder and Chief Executive Officer |
| Mattias Munnich M.Sc. | Co-Founder |
| Erik Kullgren | Chief Financial Officer |
| Anders Lehmann Ph.D. | Chief Scientific Officer |